Pancreatic islets, transplanted into recipients with type 1 diabetes, are exposed to allogenic and autoimmune T-cell responses. We set out to develop an assay to measure these responses using PBMC. Our approach was to prepare spleen extract from the islet donors (allo-antigen) and islet extracts (auto-antigen). To our surprise, we found that spleen extracts potently inhibited the proliferation of human T cells driven by antigen (tetanus toxoid) and mitogen (anti-CD3 mAb, OKT3), whereas extracts prepared from pancreatic islets from the same donor did not suppress T-cell proliferation.
Introduction
Transplantation of pancreatic islets into recipients with T1D exposes the islets to the destructive forces of the immune system on two fronts (1) . First, being a tissue from an unrelated donor, the islets may be targeted by an allogeneic immune response (2) . This response may be exacerbated by multiple transplants, particularly if the donors share HLA alleles foreign to the recipient. Second, because the recipient's pancreatic beta cells have been destroyed by an autoimmune T-cell response, they may have a pool of memory T cells primed to respond to beta-cell antigens leading to rapid destruction of the transplanted beta cells (3) .
We set out to develop an assay that could measure T-cell responses against allo-antigens and islet auto-antigens using peripheral blood from transplant recipients. Unfortunately, current assays do not reliably measure human T-cell responses to islet antigens (4, 5) . One of the problems hampering the development of T-cell assays for islet antigens is our poor knowledge of the antigens recognized by autoreactive T cells in T1D. To circumvent this problem, we decided to use islet extracts as a source of antigen reasoning that an extract of human islets would contain most, if not all, the relevant beta-cell antigens. To this end, we developed a method for extracting tissue antigens in a format that is compatible with in vitro assays of human T-cell function (6) . To measure allogenic T-cell responses, we used the same protocol to prepare extracts of human spleen tissue from the deceased organ donors from whom the islets were isolated. In this way, we aimed to measure T-cell proliferation to islet auto-antigens, and splenic allo-antigens, using a sensitive 5,6-carboxylfluorescein diacetate succinimidyl ester (CFSE)-based proliferation assay (5, 7) .
When spleen extracts were tested against PBMC from healthy subjects, we found that the spleen extracts potently inhibited human T-cell proliferation. Here, we show that suppression of T-cell proliferation, measured by 3 H-thymidine incorporation or CFSE dilution assays, is caused by residual methylprednisolone given to the organ donors prior to organ retrieval.
Methods

Protein extraction
Spleen and islet proteins were extracted in a mixture of butanol, acetonitrile and water as described previously (6) . Spleen tissue samples were obtained from deceased organ donors with informed consent from next of kin (approved by the St Vincent's Hospital Human Research Ethics Committee, protocol No. HREC-A 011/04). Small pieces of spleen (500-2500 mg) were snap frozen in liquid nitrogen and stored at À80°C. To prepare tissue extracts, samples were homogenized in 3-10 ml of extraction solution and centrifuged at 4000 r.p.m. (3452 3 g) for 10 min. The supernatant was collected and the concentration of protein in the supernatant was determined by Bicinchoninic Acid Assay (Pierce; Thermo Fischer Scientific, Rockford, IL, USA). Spleen extracts were dispensed into sterile 5 ml tubes (BD, Franklin Lakes, NJ, USA), lyophilized and stored at À80°C.
Antibodies and inhibitors
The following mAbs were added to the proliferation assays: anti-IL-10R (Clone 3F9; Biolegend, San Diego, CA, USA), anti-CTLA-4 (clone 14D3, eBioscience, San Diego, CA, USA) and anti-transforming growth factor (TGF)-b (Clone 9016.2; Thermo Scientific) were used at the final concentrations indicated in the figures. Isotype-matched control mAbs were included at the same concentrations. The indoleamine 2,3 dioxygenase (IDO) inhibitor, 1-methyl tryptophan, arginine and Indomethacin were all purchased from Sigma-Aldrich (Castle Hill, New South Wales, Australia). Mifepristone (Invitrogen Life Technologies, Carlsbad, CA, USA) was dissolved in DMSO (Sigma-Aldrich) and used at the concentrations indicated in the figures. In the DMSO, only controls DMSO was added to give the same final DMSO concentration as in the mifepristone-treated cultures.
Cell culture and proliferation assays
All assays were performed in RPMI 1640, medium (Glutamax, Gibco, Rockville, MA, USA), supplemented with 5% pooled male human serum, 2 mM glutamine (Glutamax, Gibco), penicillin (100 U ml À1 ), streptomycin (100 mg ml À1 ) and 100 mM nonessential amino acids (all from Gibco), referred to as RPMI/5% pooled human serum (PHS H-thymidine incorporation during the final 18 h of a 72-hour culture, as described previously (7, 8) .
The CFSE proliferation assays were performed as described previously (5, 9) . Briefly, PBMC were labeled with 0.1 lM CFSE (Invitrogen, Grand Island, NY, USA) and cultured (1 3 10 6 cells in 1.0 ml were cultured in sterile 5.0 ml tubes) with or without antigen and OKT3. After 7 days of culture, the cells were washed in PBS and stained on ice with anti-human CD4-AlexaFluor-647 (clone OKT4, conjugated in-house). Optimal compensation and gain settings for the flow cytometer were determined for each experiment based on unstained and single-stained samples. Propidium iodide was used to exclude dead cells. CD4
+ T-cell proliferation was measured by determining the number of CD4 + , CFSE dim cells for every 5000 CD4 + CFSE bright cells. The results are presented as a cell division index which is the ratio of the number of CD4
+ cells that have proliferated in the presence of antigen: without antigen (7).
Measurement of methylprednisolone in spleen extract
Methylprednisolone was measured in 100 lg of spleen extract using the method of McWhinney et al. (10) . Briefly, 100 ll of internal standard (500 nmol l À1 d2-methylprednisolone) was added to each tube containing 100 lg of spleen extract. The tube was dried under nitrogen at 50°C. The samples were reconstituted in 125 ll of 40% methanol, transferred to vials and 20 ll was directly injected onto the Ultra Performance Liquid Chromatography Mass Spectrometry (UPLC/MS/MS) system. The eluant was chromatographed using a Waters ACQUITY BEH C18 column (2.1 3 50 mm) with a water/methanol/ammonium acetate gradient. A Waters Premier XE mass spectrometer (Waters Corp, Milford, MA, USA) set in positive electrospray mode was used to quantify methylprednisolone by monitoring two transitions. Results were processed using MassLynx 4.1 software (Waters Corp). The chromatography time was 3 min per sample. The concentration of methylprednisolone was determined by comparison with a multi-level calibrator (10-2000 nmol l
À1
).
Statistical analysis
Differences in protein yield were analyzed by two-sided Student's t test. P < 0.05 was considered to be a significant difference.
Results
Human spleen extracts potently suppressed the anti-CD3 (OKT3) driven proliferation of human PBMC (Fig. 1) . As little as 10 ng ml À1 of spleen extract almost completely inhibited T-cell proliferation. In contrast, PHS, prepared in a similar manner, had little effect on T-cell proliferation. Spleen extracts also suppressed proliferation in response to the 2 Organ-donor spleen extracts suppress T-cell responses
CD56+CD3+ cells in lung cancer 449
antigen tetanus toxoid (Fig. 1B) indicating that antigendriven responses are susceptible to spleen extract-mediated suppression. To test if the suppression was due to toxicity of the spleen extract, PHA-activated PBMC were labeled with CFSE and cultured with spleen extracts and IL-2. Proliferation did not decrease in the presence of spleen extract, indicating the extract was not directly toxic to human T cells and did not suppress the proliferation of activated T cells in the presence of IL-2 (Fig. 1C) .
To determine if suppression of human T-cell proliferation by spleen extract required IL-10 signaling, TGFb, or CD152 (CTLA-4), blocking mAbs to these molecules, or isotype controls, were added to the cultures. None of these mAbs reversed the suppression of T-cell proliferation ( Fig. 2A-C) . The IDO inhibitor, 1-methyl tryptophan, did not reverse the spleen extract suppression (Fig. 2D) To determine if denatured spleen proteins could suppress T-cell responses, the extracts were denatured by: heating, treatment with the reducing agent dithiothreitol or reconstituting in 8 M urea. None of these treatments had any effect on the response to spleen extract (Fig. 3A-C.) To determine if the effect depended upon intact spleen proteins, we digested the spleen extracts with proteinase K. Following this treatment, the spleen extracts maintained their capacity to suppress human T-cell responses driven by OKT3, whereas pooled human serum treated in the same manner had no impact upon the OKT3-driven proliferation (Fig. 3C) . We concluded that the suppression of T-cell proliferation was not dependent upon protein(s) in the spleen extract.
In light of these data, we hypothesized that the suppressive effect we observed may be due to residual methylprednisolone in the spleen extracts. This is possible because deceased organ donors are commonly given the immunosuppressive glucocorticoid, methylprednisolone, prior to death and the collection of their organs to prevent death associated inflammation (11) (12) (13) . To address this, we compared suppression by spleen extracts from four deceased organ donors who received methylprednisolone to suppression mediated by spleen extracts from two donors who had not received methylprednisolone. All spleen extracts from the methylprednisolone treated donors suppressed OKT3-driven T-cell proliferation (Fig. 4A) . In contrast, spleen extracts from two deceased organ donors, who did not receive methylprednisolone prior to organ collection, did not suppress T-cell proliferation (Fig. 4A) .
Next, we sought to determine how much methylprednisolone was required to suppress human anti-CD3 driven human T-cell proliferation in vitro. Titration experiments revealed that the IC 50 of methylprednisolone in these assays was ;65 ng ml À1 (Fig. 4B) . Analysis of spleen samples from five organ donors who had received methylprednisolone revealed that they contained from 23 to 90 ng per 100 lg of spleen extract. No methylprednisolone was detected in the spleen lysate from an organ donor who did not receive methylprednisolone. The level ). Proliferation was measured by CFSE dilution after a further 3 days of culture. One representative of two independent experiments is shown. In all experiments, each point represents the number of CD4+, CFSE dim events per 5000 CD4+, CFSE bright events for triplicate. Each point is the mean of triplicate samples and representative of three independent experiments. of suppression correlated with the concentration of methylprednisolone detected in each extract (Fig. 4C) .
To confirm the role of methylprednisolone, we added the glucocorticoid receptor antagonist, mifepristone, to cultures containing spleen extracts from organ donors who had received methylprednisolone. Mifepristone caused a dosedependent reversal of the spleen-extract-mediated suppression of T-cell proliferation (Fig. 5) . This confirmed that the residual methylprednisolone mediates the suppression of T-cell responses observed in our cultures. In contrast, an extract prepared from pancreatic islets did not suppress the proliferation of human T cells in vitro, while the same concentration of spleen extract, from the same donor, markedly suppressed proliferation in a mifepristone dependent manner (Fig. 5B) . This is consistent with our earlier observation that pancreatic islet extracts prepared using our protocol can stimulate human insulin-specific CD4 + T-cell clones (6, 8, 14) .
Discussion
Here, we show that sufficient methylprednisolone accumulates in the spleen of organ donors to suppress T-cell responses in vitro. Our conclusion, that methylprednisolone mediates the suppression, comes from several lines of evidence. First, we showed that the spleen extracts inhibited both antigen-and mitogen-driven proliferation but were not toxic to the cells. Second, we showed that the suppression was not immunological or mediated by amino acid deficiency. Third, we showed that intact protein was not required, implicating a small molecule. Fourth, extracts from deceased organ donors who were not administered methylprednisolone did not suppress T-cell proliferation. Fifth, we show that methylprednisolone is found at concentrations that suppress human T-cell proliferation in spleen extracts from organ donors who were treated with methylprednisolone. Finally, suppression of T-cell proliferation was reversed when mifepristone was added to the cultures. Our results raise the question: does residual methylprednisolone enhance the acceptance of grafts, at least in the short term, after transplantation? Methylprednisolone is administered to organ donors before their death and the collection of their organs (13, 15, 16) . This treatment prevents organ damage caused by inflammatory responses that occur when a patient dies improving the quality of the 
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any beneficial effect after transplantation. We found that extracts of spleen tissue, but not islets, suppressed antigen-and mitogen-driven T-cell proliferation. These observations suggest that more methylprednisolone accumulates in the spleen than the islets. We have not tested other tissues so it remains to be determined whether other tissues accumulate methylprednisolone at similar concentrations to the spleen. Traces of methylprendnisolone may help to prevent graft rejection immediately after transplantation, but based on our data, it seems unlikely that there would be sufficient methylprednisolone in the islets to confer any clinical benefit to the islet transplant recipient.
The novel finding from this work is that methylprednisolone accumulates in the spleen of deceased organ donors who received it prior to death. This observation has important implications for the use of material isolated from human spleen. In our case, attempts to use human spleen extracts as a source of antigen were thwarted by the presence of residual methylprednisolone. The analysis of immune cells derived from human spleen may also be affected by methylprednisolone. Indeed, the phenotype of dendritic cell isolated from the spleens of deceased organ donors has been shown to be affected by methylprednisolone treatment (17) . We found no evidence that methylprednisolone accumulates in the pancreatic islets at concentrations high enough to suppress human T-cell proliferation in vitro (>10 ng per 100 mg of extract). Nonetheless, it remains to be determined if methylprednisolone is present in other tissues at concentrations similar to those found in the spleen (;20-100 ng per 100 mg of extract). Based on our results, analysis of cells or extracts from methylprednisolone-treated donors should take into account the possibility that methylprednisolone may affect the results.
Our original goal of measuring allo-and auto-immune responses using spleen and islet extracts as allo-and autoantigens respectively needs to be modified to account for the presence of methylprednisolone in the tissue extracts. Most deceased organ donors receive methylprednisolone prior to organ collection so simply using tissue that has not been exposed to methylprednisolone is not feasible. Blocking the effects of methylprednisolone is the alternative approach. Because we found that addition of mifepristone completely reversed the inhibitory effect of spleen lysates on human T-cell proliferation, miferpristone could be added to the cultures to counteract the effects of methylprednisolone. We found no evidence that mifepristone stimulated human T-cell proliferation in the absence of mitogenic anti-CD3 mAb, nor did it augment the CD3-driven proliferation above the levels seen without spleen extract (Fig. 4B) . Hence, there is no evidence that mifepristone has any other effects upon human T cells in these assays.
Our organic solvent-based extraction protocol may have enriched methylprednisolone in the tissue extracts. This protocol was chosen because it gives the greatest yield of proteins of the solvent mixtures tested (6) . Detergents were avoided because of the technical problems associated with removing these chemicals from the tissue extract, whereas organic solvents used in our extraction protocol can be removed by lyophilization. In conclusion, we show that methylprednisolone accumulates in the spleens of deceased organ donors to concentrations that inhibit human T-cell proliferation. The presence of immunosuppressive drugs in tissue extracts should be considered in studies using deceased organ-donor-derived extracts as antigens in assays of immune function.
Supplementary data
Supplementary data are available at International Immunology Online. . Each point is the mean of triplicate wells and this is representative of three independent experiments. Statistically significant differences between mifepristone and DMSO-treated samples are indicated (***P < 0.0001; **P < 0.001; *P < 0.05; NS P > 0.05). Islet extract does not suppress T-cell proliferation. (B) PBMC were cultured with anti-CD3 and either spleen extract (pooled from three donors, 'pooled spleen'), spleen from donor #32 (spleen #32) or islet extract from the same donor (islet #32). Responses in the presence of mifepristone (1 lM) or the equivalent volume of DMSO were compared. The mean of triplicate wells and SEM is shown. One representative of two independent experiments is shown. Fig. 4 . Spleen extracts from organ donors treated with methylprednisolone suppress T-cell responses in vitro. (A) PBMC from a healthy donor were cultured with anti-OKT3 (10 ng ml À1 ) in the presence of 100 lg ml À1 of spleen extract from two organ donors who did not receive methylprednisolone and four who did. The dotted line represents the proliferation driven by anti-CD3 mAb alone (17 793 c.p.m.). Each point is the mean of triplicate wells and one representative of two experiments is shown. The difference between the two groups is statistically significant (**P < 0.001). Methylprednisolone at >10 ng ml À1 suppress human T-cell proliferation. (B) Methylprednisolone (10.0 ng ml À1 to 100 lg ml
À1
) was added to cultures of PBMC from a healthy donor in the presence of anti-OKT3 (10 ng ml
). Each point is the mean of triplicate wells and one representative of three experiments is shown. (C) The concentration of methylprednisolone detected in the spleen extracts correlates with the suppression of human PBMC proliferation. The concentration of methylprednisolone in 100 lg of spleen extract from six donors was measured in triplicate by mass spectrometry (x-axis). Spleen mean 6 SEM of triplicate measures. One representative of three experiments is shown.
